DK1163003T3 - Behandling af LFA-1 associerede lidelser med ögende doser af LFA-1-antagonist - Google Patents

Behandling af LFA-1 associerede lidelser med ögende doser af LFA-1-antagonist

Info

Publication number
DK1163003T3
DK1163003T3 DK00916502T DK00916502T DK1163003T3 DK 1163003 T3 DK1163003 T3 DK 1163003T3 DK 00916502 T DK00916502 T DK 00916502T DK 00916502 T DK00916502 T DK 00916502T DK 1163003 T3 DK1163003 T3 DK 1163003T3
Authority
DK
Denmark
Prior art keywords
lfa
dose
antagonist
treatment
increasing doses
Prior art date
Application number
DK00916502T
Other languages
English (en)
Inventor
Karen Starko
Russell L Dedrick
Marvin R Garavoy
Susan M Kramer
Original Assignee
Genentech Inc
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Xoma Technology Ltd filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1163003T3 publication Critical patent/DK1163003T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK00916502T 1999-03-19 2000-03-17 Behandling af LFA-1 associerede lidelser med ögende doser af LFA-1-antagonist DK1163003T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27304399A 1999-03-19 1999-03-19
US12522899P 1999-03-19 1999-03-19
US12535199P 1999-03-19 1999-03-19
PCT/US2000/007189 WO2000056363A1 (en) 1999-03-19 2000-03-17 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist

Publications (1)

Publication Number Publication Date
DK1163003T3 true DK1163003T3 (da) 2009-11-30

Family

ID=27383217

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00916502T DK1163003T3 (da) 1999-03-19 2000-03-17 Behandling af LFA-1 associerede lidelser med ögende doser af LFA-1-antagonist

Country Status (11)

Country Link
US (1) US6652855B1 (da)
EP (2) EP1854480A3 (da)
JP (1) JP2002540078A (da)
AT (1) ATE439145T1 (da)
AU (1) AU764382B2 (da)
CA (1) CA2367025A1 (da)
DE (1) DE60042735D1 (da)
DK (1) DK1163003T3 (da)
ES (1) ES2331643T3 (da)
IL (2) IL145480A0 (da)
WO (1) WO2000056363A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
MX2010007393A (es) * 2008-01-03 2010-11-09 Abbott Biotech Ltd Anticipacion de eficacia a largo plazo de un compuesto en el tratamiento de psoriasis.
JP2012254994A (ja) * 2012-07-23 2012-12-27 Trion Pharma Gmbh 癌治療のための抗体およびグルココルチコイドの組み合わせ

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT8121814V0 (it) 1981-05-19 1981-05-19 Nordica Spa Struttura di scarpetta interna particolarmente per scarponi da sci.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988006592A1 (en) 1987-02-26 1988-09-07 Dana-Farber Cancer Institute, Inc. Cloning of lfa-1
DE3854536T2 (de) 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5002869A (en) 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5071964A (en) 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
NO900155L (no) 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2050329A1 (en) 1989-03-09 1990-09-10 Timothy A. Springer Method of treating viral infections using lfa-1
NZ245651A (en) 1989-03-09 1997-06-24 Blood Res Center Ligand molecules (e.g. antibodies and fragments) capable of binding to intercellular adhesion molecule-2 (icam-2) and their use
JP3048632B2 (ja) 1989-06-02 2000-06-05 ザ ジョーンズ ホプキンズ ユニヴァーシティ スクール オブ メディスン 白血球付着レセプターβ鎖に対するモノクローナル抗体と、この抗体の製造方法と、その応用
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
WO1991018011A1 (en) 1990-05-15 1991-11-28 Swinburne Limited Inhibition of cell adhesion using intercellular adhesion molecule-1-like peptides and/or analogues thereof
JPH06511156A (ja) 1992-07-16 1994-12-15 イコス　コーポレイション 炎症性疾患状態に関連する症状の緩和
MX9305070A (es) * 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
ATE267257T1 (de) * 1996-11-27 2004-06-15 Genentech Inc Humanisierte anti-koerper gegen cd11a
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies

Also Published As

Publication number Publication date
EP1854480A2 (en) 2007-11-14
ATE439145T1 (de) 2009-08-15
CA2367025A1 (en) 2000-09-28
ES2331643T3 (es) 2010-01-12
EP1163003A1 (en) 2001-12-19
AU764382B2 (en) 2003-08-14
EP1854480A3 (en) 2009-04-01
JP2002540078A (ja) 2002-11-26
EP1163003B1 (en) 2009-08-12
AU3759700A (en) 2000-10-09
US6652855B1 (en) 2003-11-25
DE60042735D1 (de) 2009-09-24
WO2000056363A1 (en) 2000-09-28
IL145480A (en) 2011-04-28
IL145480A0 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
AU2001296547A1 (en) Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
DK0879820T3 (da) Benzamidanaloger anvendelige som PARP (ADP-Ribosyltransferase, ADPRT) DNA-reparations enzyminhibitorer
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
NO20051048L (no) Terapeutisk humant anti-IL-1R1 monoklonalt antistoff
DK0682514T3 (da) Anvendelse af lokalanæstetiske midler til fremstilling af et lægmiddel til behandling af bronchial astma
GEP20002032B (en) (54) Pyrido[2,3-d]Pyrimidines and Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Composition Comprising Them and Methods of Treatment
DE602004023961D1 (de) Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
EP0933993A4 (en) SUBSTITUTED CYCLOPENTANE COMPOUNDS SUITABLE AS NEURAMINIDASE INHIBITORS
SE9802208D0 (sv) Novel compounds
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
EA199900633A1 (ru) Способы терапевтического введения анти-cd40l соединений
DK1163003T3 (da) Behandling af LFA-1 associerede lidelser med ögende doser af LFA-1-antagonist
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
EE9400296A (et) Piperidinüültioindooli derivaadid, ravimvormid, aktiivne valuvaigisti, nende valmistamise meetodid
WO2000033874A3 (en) Boron neutron capture therapy using pre-targeting methods
DK694188D0 (da) Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
CA2368676A1 (en) Sphingomyelin containing preparation
NZ246748A (en) Migraine-preventing medicaments comprising a mast cell degranulation blocking agent (e.g. hydroxyzine, ketotifen, azatadine, azelastine, cyproheptadine, oxatomide, terfenadine, etc)
NO971043L (no) Anvendelse av IL-4 for potensering av kjemoterapeutiske midler
FI842966A0 (fi) Triazolo-pyrimidinderivat, foerfarande foer deras framstaellning samt deras terapeutiska anvaendning som hjaertmediciner.